Genomic Profiling of the Hallmarks of Cancer

References

• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–14.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
   PubMed Web of Science ®Google Scholar
• Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer. 2010;10:232–33.
   PubMed Web of Science ®Google Scholar
• Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res. 2017;7:1016–36.
   PubMed Web of Science ®Google Scholar
• Sonnenschein C, Soto AM. The aging of the 2000 and 2011 hallmarks of cancer reviews: a critique. J Biosci. 2013;38:651–63.
   PubMed Web of Science ®Google Scholar
• Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–D47.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Beare D, Bindal N, Bamford S, Ward S, Cole CG, Jia M, Kok C, Boutselakis H, De T, et al. COSMIC: high-resolution cancer genetics using the catalogue of somatic mutations in cancer. 2016.
   Google Scholar
• Uguen A, De Braekeleer M. ROS1 fusions in cancer: a review. Future Oncol. 2016;12:1911–28.
   PubMed Web of Science ®Google Scholar
• Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37–52.
   PubMed Web of Science ®Google Scholar
• Xiong Q, Chan JL, Zong CS, Wang LH. Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth. Mol Cell Biol. 1996;16(4):1509–18.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou SH, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, et al. Crizotinib in ROS1 -rearranged non–small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71. doi:10.1056/NEJMoa1406766.
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;1(1):1–16. doi:10.1200/PO.17.00011.
   Web of Science ®Google Scholar
• Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother. 2011;60(8):1161–71.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635–47.
   PubMed Web of Science ®Google Scholar
• Prunier C, Baker D, Ten Dijke P, Ritsma L. TGF-beta family signaling pathways in cellular dormancy. Trends Cancer. 2019;5(1):66–78.
   PubMed Web of Science ®Google Scholar
• Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2003;82(3):199–206.
   PubMed Web of Science ®Google Scholar
• Oshimori N, Oristian D, Fuchs E. TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell. 2015;160(5):963–76.
   PubMed Web of Science ®Google Scholar
• Neel JC, Humbert L, Lebrun JJ. The dual role of TGF-beta in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol. 2012;1–28. doi:10.5402/2012/381428.
   Google Scholar
• Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994;371:257–61.
   PubMed Web of Science ®Google Scholar
• Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994;8(1):9–22.
   PubMed Web of Science ®Google Scholar
• Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006;66(4):2202–09.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Mose ES, Montel V, Tarin D. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol. 2006;169(2):673–81.
   PubMed Web of Science ®Google Scholar
• Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012;150(4):764–79.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–12.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761–73.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840. doi:10.3390/ijms20040840.
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059.
   PubMed Web of Science ®Google Scholar
• Huang C-Y, Chung C-L, Hu T-H, Chen J-J, Liu P-F, Chen C-L. Recent progress in TGF-β inhibitors for cancer therapy. Biomed Pharmacother Biomed Pharmacotherapie. 2021;134:111046. doi:10.1016/j.biopha.2020.111046.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924–40. doi:10.1016/j.immuni.2019.03.024.
   PubMed Web of Science ®Google Scholar